Vulvar & Vaginal Cancer Digest

The Month in Vaginal & Vulvar Cancer Research

April 2026

Vaginal Cancer

Vaginal cancer is one of the rarest gynecologic cancers, accounting for roughly 1-3% of all gynecologic cancer diagnoses. Because so few cases are diagnosed each year, the research base grows slowly, which makes every new study count. April was a modest month for vaginal cancer literature, yielding four open-access papers directly relevant to this community: a meta-analysis on treatment outcomes for high-grade vaginal precancerous lesions, a surgical case report on managing post-radiation vaginal recurrence, a systematic review on a rare anatomical condition linked to vaginal and cervical cancer, and a broad review of sexual health in gynecologic cancer survivors.

The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist. This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused.

Understanding the risk of high-grade vaginal precancerous lesions and which treatments work best

Vaginal intraepithelial neoplasia (VaIN) refers to abnormal cell changes in the vaginal lining that can, if left untreated, develop into invasive vaginal cancer. Most of what's known about treating high-grade VaIN (grade 2 or 3, which carry the most significant risk of progressing to cancer) has come from small individual studies, making it hard to know which approach is most reliable.

A new systematic review and meta-analysis pooled data from 15 retrospective studies of people treated for high-grade VaIN (VaIN 2+) to assess which treatments work best and what factors predict failure. The analysis found that topical therapies, creams or gels applied directly to the vaginal tissue, had a significantly higher risk of treatment failure compared to laser ablation, which uses focused light energy to destroy abnormal tissue. Surgical excision and laser ablation showed comparable outcomes to each other. The most important risk factor for treatment failure was immunosuppression, meaning a weakened immune system: people in this group were twice as likely to experience recurrence. Prior hysterectomy, multifocal disease (lesions in multiple spots), and HPV 16 infection were not found to be statistically significant predictors of recurrence in the pooled analysis, though the authors note the underlying evidence comes entirely from retrospective studies and call for prospective research to confirm these findings. (Read the full paper)

Surgical management of vaginal cancer that returns after radiation therapy

Managing vaginal cancer or cervical cancer that recurs in the vaginal wall after prior radiation therapy is among the most technically difficult challenges in gynecologic oncology. Radiation changes the tissue permanently, making surgery more complex, healing slower, and the risk of complications like fistulas (abnormal connections between organs) higher than in unirradiated tissue.

A published case report documents the care of a 51-year-old woman with squamous cell carcinoma recurrence in the vaginal wall four years after radiation treatment for stage IIIb cervical cancer. The case is notable for the surgical team's use of a pedicled omental flap (a section of the omentum, the apron-like tissue that covers the abdominal organs), still attached to its own blood supply, that was repositioned to fill the vaginal cavity after a total vaginectomy (surgical removal of the vagina). The omentum's rich blood supply and immune function were used deliberately to promote healing, reduce infection risk, and prevent fistula formation between the bladder and rectum, complications that are especially dangerous after prior pelvic radiation. At the three-month follow-up, imaging showed no evidence of residual or new disease, and the patient reported good quality of life. Because this is a single case report, not a clinical trial or large study, its findings illustrate a potential surgical approach rather than establishing it as a standard; individual decisions about surgery for recurrent disease must always be made in a multidisciplinary team setting. (Read the full paper)

A rare anatomical condition that creates a hidden blind spot for vaginal and cervical cancer

Obstructed hemivagina and ipsilateral renal anomaly syndrome (known as OHVIRA or Herlyn-Werner-Wunderlich syndrome) is a rare Müllerian malformation, meaning it involves an abnormality in the structures that develop into the female reproductive system before birth. OHVIRA creates a doubled uterus with one vaginal canal that is completely blocked, often staying undetected until puberty when menstrual blood cannot drain. Because one side of the reproductive anatomy is hidden, tumors that develop in the obstructed compartment may not be visible on standard examination.

A systematic review identified and analyzed 21 reported cases of gynecologic cancers arising in people with OHVIRA syndrome, drawing on PubMed and Scopus through January 2026, plus one new institutional case. The authors found that most tumors occurred in the lower genital tract, the vagina and cervix, and that adenocarcinoma (a cancer arising from glandular tissue), particularly the clear cell subtype, appeared frequently. Clear cell adenocarcinoma of the vagina is a rare and distinct subtype of vaginal cancer associated with specific risk factors; its appearance in the blocked or obstructed compartment of OHVIRA anatomy underscores the diagnostic blind spot this condition creates. The review concludes that clinicians should maintain a high level of suspicion in people with OHVIRA, use MRI-based imaging to fully map anatomy, and evaluate each compartment separately in symptomatic patients. Because this review synthesizes case reports and small case series, it cannot establish how common cancer is among all people with OHVIRA, but it provides important clinical guidance for a population that has often been missed. (Read the full paper)

What Does This Mean for Me?

If you have been diagnosed with high-grade VaIN, treatment matters and so does your follow-up. The new meta-analysis finding that topical therapies are less reliable than ablative or surgical treatments may be worth discussing with your gynecologic oncologist or colposcopist, particularly if you have had prior treatment for VaIN that didn't fully resolve the lesion. If you have any condition that affects your immune system, including HIV, autoimmune disease, or immunosuppressive medication, the research confirms that you may be at higher risk for recurrence and may benefit from closer surveillance after treatment. Ask your care team: "Given my health history, which treatment approach gives me the best chance of clearing this lesion, and how often should I be followed up with afterward?"

If you have had pelvic radiation, recurrence is a conversation worth having. The case report from this month illustrates how complex vaginal cancer management becomes when prior radiation is involved, and why that type of care requires a team with specific expertise. If you or someone you love has had pelvic radiation for cervical cancer and is experiencing new symptoms, including vaginal bleeding, pelvic pressure, or pain, please raise it with your care team. Early detection of any recurrence maximizes treatment options.

If you have OHVIRA or a known Müllerian anomaly, ask your care team about surveillance. The review this month highlights that the obstructed side of OHVIRA anatomy may harbor lesions that are invisible on routine examination. If you have this condition, asking your gynecologist about MRI-based evaluation and whether vaginal cancer surveillance is appropriate for your specific anatomy is a reasonable step.

Vaginal cancer is rare enough that research depends heavily on the people who participate in clinical trials, share their experiences in registries, and advocate for this disease. Every person who participates helps build the evidence base that makes care better for the next person. If you're interested in finding a clinical trial, visit ocrahope.org or speak with your care team about open studies near you.

Vaginal cancer patients are welcome to participate in OCRA support, peer mentorship, and education programs, which are open to all members of the gynecologic cancer community. Learn about our patient programs here.

This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.

Sources

Directly Referenced in This Digest

Ługowski F, et al. "Comparative Efficacy of Treatment Methods and Risk Factors for Treatment Failure in High-Grade Vaginal Intraepithelial Neoplasia: A Systematic Review and Meta-Analysis." Cancers (Basel). April 20, 2026. PMID 42073625. https://doi.org/10.3390/cancers18081302
Shu H, et al. "Application of omental flap in total vaginectomy for post-radiotherapy recurrent cervical cancer: a case report." Frontiers in Surgery. April 10, 2026. PMID 42038500. https://doi.org/10.3389/fsurg.2026.1779661
Parisi G, et al. "Gynecologic Malignancies in Obstructed Hemivagina and Ipsilateral Renal Anomaly (OHVIRA) Syndrome: A Systematic Review." Journal of Clinical Medicine. April 8, 2026. PMID 42074625. https://doi.org/10.3390/jcm15082824

Additional Open-Access Papers Published in April 2026 on Related Topics

Marino P, et al. "Oncosexology: A Narrative Review on Sexual Health and Quality of Life in Cancer Patients." Cancer Medicine. April 2026. PMID 42014931. https://doi.org/10.1002/cam4.71864 (Broad narrative review covering sexual dysfunction across cancer types, including a dedicated section on gynecologic cancers - cervical, vaginal, ovarian, and uterine - and the role of multidisciplinary oncosexology care in improving quality of life for survivors. Relevant for understanding the sexual health challenges that may accompany vaginal cancer treatment.)

Papers Excluded Due to Licensing Restrictions

The following papers address topics relevant to the community and may be openly available but have licensing terms that are unclear or do not permit inclusion in this digest.

Asher N, et al. "Vulvar and Vaginal Melanoma: Real-world Clinical Outcomes and Prognostic Differences From a Single-center Experience." Journal of Lower Genital Tract Disease. April 27, 2026. PMID 42044311. https://doi.org/10.1097/LGT.0000000000000959 (Retrospective single-center analysis of 39 patients with vulvar or vaginal melanoma examining clinical course, response to immunotherapy - including anti-PD-1 agents and combination immunotherapy - and survival outcomes, with comparison of outcomes between vulvar and vaginal primary sites.)
Indraccolo U, Favilli A. "The Progression of Vaginal Intraepithelial Neoplasia to Cancer: A Systematic Review and Meta-Analysis." Journal of Women's Health. April 6, 2026. PMID 41943441. https://doi.org/10.1177/15409996261438757 (Systematic review and meta-analysis of 30 case series estimating the risk of progression from VaIN to invasive vaginal cancer, with separate analyses for treated and untreated high-grade VaIN.)

Vulvar Cancer

Vulvar cancer is rare, accounting for roughly 5% of gynecologic cancer diagnoses, and monthly research output reflects that: April yielded 10 confirmed papers. This digest covers a single open-access paper with a permitted license, which offers meaningful data on how vulvar cancer is being diagnosed and treated in an understudied part of the world. The remaining nine papers this month spanned sentinel lymph node biopsy technique, precancerous lesion classification, vulvar melanoma immunotherapy, rare adenocarcinoma subtypes, HPV vaccination practices, and surgical outcomes. They are listed in full in the licensing-excluded section below.

Vulvar cancer cases are rising in Indonesia and the stage of the cancer at diagnosis matters greatly

Research from communities outside Western Europe and North America is rare but important: vulvar cancer may present differently, at different stages, and under different healthcare constraints depending on where someone lives. Understanding what drives late diagnosis in diverse settings is one step toward addressing it.

A six-year retrospective study from Indonesia's national cancer referral center, Dr. Cipto Mangunkusumo Hospital, analyzed 86 cases of vulvar cancer diagnosed between 2015 and 2020. The number of cases managed at this center increased significantly over the study period, at an average rate of about 21% per year, with the sharpest rise among women over 60 and among patients from rural areas. Nearly 80% of patients were diagnosed at an advanced stage, a much higher proportion than is typical in high-income countries. The researchers identified several factors associated with advanced disease at presentation, including larger tumors, bilateral involvement (cancer affecting both sides of the vulva), and urban residence - a counterintuitive finding the authors suggest may reflect referral delays and socioeconomic pressures particular to dense urban areas in Indonesia's healthcare system. Separately, factors linked to cancer having already spread to distant organs included lower body weight, the presence of vulvar pain, a non-keratinized tumor subtype (a specific histological pattern associated with more aggressive behavior), and right-sided tumor location. The study does not represent national incidence rates and its sample size is modest, but it is the most comprehensive analysis of vulvar cancer patterns from Indonesia to date, and it points toward the importance of earlier detection and improved referral pathways in underserved settings. (Read the full paper)

What Does This Mean for Me?

If you have been diagnosed with vulvar cancer later than you feel you should have been, you are not alone. Diagnostic delay is a recognized and documented problem in vulvar cancer, in multiple countries and health systems. Research like the Indonesian study highlights how structural barriers, including where someone lives, their access to healthcare, and cultural and systemic factors, shape whether a diagnosis comes early or late. Bringing persistent vulvar symptoms, a lump, a sore that doesn't heal, pain, or bleeding, to a clinician promptly is always the right step, even if it feels embarrassing or you've been reassured before.

If you or someone you care for lives in a rural area or has difficulty accessing specialized gynecologic care, the evidence from this study and others points to real disparities in stage at diagnosis for people in underserved communities. Asking your primary care provider for a referral to a gynecologic oncologist, a specialist in cancers of the reproductive system, earlier rather than later can make a meaningful difference. OCRA's online "Find a Doctor" tool may help you locate a gynecologic cancer specialist in your area.

Because vulvar cancer is rare, the research community depends on patients and survivors who are willing to participate in clinical trials and registries. Visit ocrahope.org or ask your care team about clinical studies that may be open to you.

Vulvar cancer patients are welcome to participate in OCRA support, peer mentorship, and education programs, which are open to all members of the gynecologic cancer community. Learn about our patient programs here.